KR20150013170A - 페닐아세트산 전구약물의 치료적 모니터링 방법 - Google Patents

페닐아세트산 전구약물의 치료적 모니터링 방법 Download PDF

Info

Publication number
KR20150013170A
KR20150013170A KR1020147032114A KR20147032114A KR20150013170A KR 20150013170 A KR20150013170 A KR 20150013170A KR 1020147032114 A KR1020147032114 A KR 1020147032114A KR 20147032114 A KR20147032114 A KR 20147032114A KR 20150013170 A KR20150013170 A KR 20150013170A
Authority
KR
South Korea
Prior art keywords
paa
dose
pagn
prodrug
target range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147032114A
Other languages
English (en)
Korean (ko)
Inventor
브루스 샤르슈미트
마소우드 모크타라니
Original Assignee
하이페리온 쎄라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49380684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150013170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 하이페리온 쎄라퓨틱스, 인크. filed Critical 하이페리온 쎄라퓨틱스, 인크.
Priority to KR1020197029026A priority Critical patent/KR102264579B1/ko
Publication of KR20150013170A publication Critical patent/KR20150013170A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
KR1020147032114A 2012-04-20 2012-09-11 페닐아세트산 전구약물의 치료적 모니터링 방법 Withdrawn KR20150013170A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020197029026A KR102264579B1 (ko) 2012-04-20 2012-09-11 페닐아세트산 전구약물의 치료적 모니터링 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636256P 2012-04-20 2012-04-20
US61/636,256 2012-04-20
PCT/US2012/054673 WO2013158145A1 (en) 2012-04-20 2012-09-11 Methods of therapeutic monitoring of phenylacetic acid prodrugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197029026A Division KR102264579B1 (ko) 2012-04-20 2012-09-11 페닐아세트산 전구약물의 치료적 모니터링 방법

Publications (1)

Publication Number Publication Date
KR20150013170A true KR20150013170A (ko) 2015-02-04

Family

ID=49380684

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197029026A Active KR102264579B1 (ko) 2012-04-20 2012-09-11 페닐아세트산 전구약물의 치료적 모니터링 방법
KR1020147032114A Withdrawn KR20150013170A (ko) 2012-04-20 2012-09-11 페닐아세트산 전구약물의 치료적 모니터링 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197029026A Active KR102264579B1 (ko) 2012-04-20 2012-09-11 페닐아세트산 전구약물의 치료적 모니터링 방법

Country Status (25)

Country Link
US (4) US9561197B2 (enExample)
EP (2) EP3222275B1 (enExample)
JP (3) JP6234436B2 (enExample)
KR (2) KR102264579B1 (enExample)
CN (3) CN104540507A (enExample)
AU (3) AU2012377389A1 (enExample)
BR (1) BR112014026138A2 (enExample)
CL (2) CL2014002807A1 (enExample)
CY (1) CY1118838T1 (enExample)
DK (1) DK2846791T3 (enExample)
EC (1) ECSP14024561A (enExample)
ES (2) ES2807951T3 (enExample)
HR (1) HRP20170651T1 (enExample)
HU (1) HUE032726T2 (enExample)
IL (2) IL235127A (enExample)
LT (1) LT2846791T (enExample)
MX (1) MX365302B (enExample)
PL (1) PL2846791T3 (enExample)
PT (1) PT2846791T (enExample)
RS (1) RS55870B1 (enExample)
SG (2) SG10201608749UA (enExample)
SI (1) SI2846791T1 (enExample)
SM (1) SMT201700219T1 (enExample)
WO (1) WO2013158145A1 (enExample)
ZA (1) ZA201407597B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107271696A (zh) 2011-09-30 2017-10-20 海波龙治疗有限责任公司 氮清除药物的治疗性监测方法
HUE032726T2 (en) 2012-04-20 2017-10-30 Horizon Therapeutics Llc HPN-100 for use in the treatment of nitrogen retention disorders
SI2922576T1 (en) 2012-11-21 2018-04-30 Horizon Therapeutics, Llc Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
WO2015057747A1 (en) 2013-10-14 2015-04-23 Hyperion Therapeutics, Inc. Methods of treating urea cycle disorders
EP3013372B1 (en) * 2014-06-04 2019-07-10 Immedica Pharma AB Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
EP0858441B1 (en) 1995-02-07 2001-05-09 Brusilow Enterprises, LLC Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
US6219567B1 (en) 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
US20100016207A1 (en) 2005-11-10 2010-01-21 Wurtman Richard J Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
GB2451259B (en) * 2007-07-25 2011-07-20 Gp Acoustics Loudspeaker
EP2237684A2 (en) 2008-01-08 2010-10-13 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
WO2009134460A1 (en) * 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
PL2330892T3 (pl) * 2008-08-29 2017-05-31 Horizon Therapeutics, Llc Sposoby leczenia z zastosowaniem leków wychwytujących amoniak
EP2338050A1 (en) 2008-08-29 2011-06-29 Ucyclyd Pharma, Inc. Dosing and monitoring patients on nitrogen-scavenging drugs
US20110020312A1 (en) * 2009-05-11 2011-01-27 Niven Rajin Narain Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
WO2011011781A1 (en) 2009-07-24 2011-01-27 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
WO2012028620A1 (en) 2010-08-31 2012-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation
CN107271696A (zh) 2011-09-30 2017-10-20 海波龙治疗有限责任公司 氮清除药物的治疗性监测方法
HUE032726T2 (en) 2012-04-20 2017-10-30 Horizon Therapeutics Llc HPN-100 for use in the treatment of nitrogen retention disorders
SI2922576T1 (en) 2012-11-21 2018-04-30 Horizon Therapeutics, Llc Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy

Also Published As

Publication number Publication date
MX365302B (es) 2019-05-29
MX2014012694A (es) 2015-06-03
WO2013158145A1 (en) 2013-10-24
JP2018039830A (ja) 2018-03-15
SG10201608749UA (en) 2016-12-29
US20180263938A1 (en) 2018-09-20
SMT201700219T1 (it) 2017-05-08
ZA201407597B (en) 2017-05-31
ES2623470T3 (es) 2017-07-11
JP6637941B2 (ja) 2020-01-29
AU2018200163A1 (en) 2018-02-01
US20180015058A1 (en) 2018-01-18
ECSP14024561A (es) 2015-09-30
AU2018200163B2 (en) 2018-12-20
CL2014002807A1 (es) 2015-02-27
HRP20170651T1 (hr) 2017-06-30
PT2846791T (pt) 2017-05-25
PL2846791T3 (pl) 2017-07-31
CY1118838T1 (el) 2018-01-10
US20170266143A1 (en) 2017-09-21
JP2015514757A (ja) 2015-05-21
IL255918A (en) 2018-01-31
AU2019201811A1 (en) 2019-04-04
IL255918B (en) 2019-06-30
JP2019219413A (ja) 2019-12-26
CN104540507A (zh) 2015-04-22
WO2013158145A9 (en) 2014-05-01
EP3222275B1 (en) 2020-06-24
DK2846791T3 (en) 2017-03-27
HK1243959A1 (en) 2018-07-27
US20130281530A1 (en) 2013-10-24
RS55870B1 (sr) 2017-08-31
EP2846791B1 (en) 2017-02-08
IL235127A (en) 2017-12-31
CL2017001375A1 (es) 2018-01-05
SI2846791T1 (sl) 2017-06-30
AU2019201811B2 (en) 2020-07-09
AU2012377389A1 (en) 2014-10-30
CN111991383A (zh) 2020-11-27
BR112014026138A2 (pt) 2017-06-27
LT2846791T (lt) 2017-04-10
KR20190116552A (ko) 2019-10-14
JP6234436B2 (ja) 2017-11-22
HUE032726T2 (en) 2017-10-30
SG11201406745VA (en) 2014-12-30
KR102264579B1 (ko) 2021-06-11
ES2807951T3 (es) 2021-02-24
EP2846791A1 (en) 2015-03-18
EP2846791A4 (en) 2015-08-19
US9561197B2 (en) 2017-02-07
CN113995743A (zh) 2022-02-01
HK1208380A1 (en) 2016-03-04
EP3222275A1 (en) 2017-09-27

Similar Documents

Publication Publication Date Title
AU2019201811B2 (en) Methods of therapeutic monitoring of phenylacetic acid prodrugs
US10183006B2 (en) Methods of therapeutic monitoring of nitrogen scavenging drugs
EP2986325B1 (en) Methods of treating urea cycle disorders
HK1243959B (en) Methods of therapeutic monitoring of phenylacetic acid prodrugs
HK1208380B (en) Hpn-100 for use in the treatment of nitrogen retention disorders
HK1219656B (en) Methods of treating urea cycle disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141117

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20170411

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170911

Comment text: Request for Examination of Application

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181128

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190624

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181128

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190624

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170914

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190909

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190820

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190624

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20181128

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170914

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191002

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20191004

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20190909

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20190624

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20210121

Appeal identifier: 2019101003304

Request date: 20191004

PN2301 Change of applicant

Patent event date: 20191023

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

J301 Trial decision

Free format text: TRIAL NUMBER: 2019101003304; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20191004

Effective date: 20210121

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20210121

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20191004

Decision date: 20210121

Appeal identifier: 2019101003304

PS0901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20210208

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20210125

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

PC1201 Submission of document of withdrawal after decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event date: 20210323

Patent event code: PC12012R01D

Comment text: Decision to Grant Registration

Patent event date: 20210208

Patent event code: PC12011S01I

WITR Withdrawal of patent application after decision to grant